IBA, NST combine in molecular imaging pact
This article was originally published in Clinica
Radiopharmaceuticals company Ion Beam Applications (IBA) and Israeli firm NeuroSurvival Technologies (NST) will work together to scale up manufacturing of the latter's Aposense molecular imaging agent and make it available to multi-center clinical trial sites in the US. Aposense targets cells that are undergoing apoptosis, or programmed cell death, a phenomenon associated with many medical disorders. The two firms will first develop the radio-chemistry and processes needed for GMP-grade radio-labelling of Aposense, making it compatible for large scale commercialisation and distribution. IBA (Louvain-la-Neuve, Belgium) and NST will both supply the radio-labelled agent to the clinical trial sites and will negotiate commercial supply terms following FDA approval of the product. Financial terms of the agreement were not revealed.